Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

329
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
329
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

Related Experiment Video

Updated: Apr 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K

Sebelipase alfa: first global approval.

Matt Shirley1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|October 11, 2015
PubMed
Summary
This summary is machine-generated.

Sebelipase alfa offers enzyme replacement therapy for lysosomal acid lipase (LAL) deficiency. This treatment reduces lipid accumulation, improving liver and lipid abnormalities in patients with LAL deficiency.

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.3K

Related Experiment Videos

Last Updated: Apr 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.3K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Lysosomal acid lipase (LAL) deficiency is a rare genetic disorder characterized by the accumulation of lipids in lysosomes.
  • This accumulation leads to severe multi-systemic complications, including dyslipidemia and liver disease.
  • Current treatment options for LAL deficiency are limited, highlighting the need for effective therapies.

Purpose of the Study:

  • To summarize the development milestones of sebelipase alfa, a novel enzyme replacement therapy for LAL deficiency.
  • To highlight the regulatory approval process and its significance for patients with LAL deficiency.

Main Methods:

  • Development of sebelipase alfa as a recombinant human LAL enzyme.
  • Administration via intravenous infusion.
  • Clinical evaluation for efficacy and safety in patients with LAL deficiency.

Main Results:

  • Sebelipase alfa demonstrated efficacy in reducing lysosomal lipid accumulation.
  • Improvements in disease-related abnormalities such as dyslipidemia and liver abnormalities were observed.
  • Received first global approval in the EU in August 2015 for LAL deficiency treatment.

Conclusions:

  • Sebelipase alfa represents a significant advancement in the treatment of LAL deficiency.
  • The enzyme replacement therapy offers a new therapeutic option for patients of all ages with LAL deficiency.
  • Successful development and approval pave the way for broader patient access to this vital treatment.